摘要
目的探讨新辅助化疗对晚期卵巢癌患者预后的影响。方法入组60例晚期卵巢癌患者,将25例直接行肿瘤细胞减灭术患者纳入对照组,将35例行肿瘤细胞减灭术前先行新辅助化疗患者纳入观察组,比较2组患者的术中出血量、手术时间、手术满意度、生存率及并发症的发生情况。结果观察组术中出血量、手术时间、手术满意度均优于对照组,差异均有统计学意义(P均<0.05);观察组并发症总发生率低于对照组,差异有统计学意义(P<0.05);2组患者1 a、3 a、5 a生存率比较差异均无统计学意义(P均>0.05)。结论对于晚期卵巢癌患者,采用新辅助化疗有助于手术的顺利进行和病灶的完成切除,并减轻了手术并发症。
Objective To evaluate the effect of neoadjuvant chemotherapy on survival prognosis of advanced ovarian cancer. Methods Sixty patients with advanced ovarian cancer were collected, 25 patients underwent cytoreductive surgery were included in the control group, 35 patients underwent eytoreduetive surgery after neoadjuvant chemotherapy were included in the observation group. The intraoperative bleeding volume, operation time, operation satisfaction, survival rate and complications were compared between the two groups. Results The intraoperatire bleeding volume, operation time, operation satisfaction in the observation group were better than those in the control group （P 〈 0. 05 ）. The total complication incidence of the observation group was lower than that of the control group （ P 〈 0.05 ）. There were no statistical significant differences in the 1-, 3-, and 5- year survival rates between the two groups （ P 〉 0.05 ）. Conclusion For the patients with advanced ovarian cancer, neoadjuvant chemotherapy before cytoreductive surgery can significantly improve the operation satisfaction, and reduce the complications.
出处
《肿瘤基础与临床》
2018年第1期25-27,共3页
journal of basic and clinical oncology
关键词
新辅助化疗
晚期卵巢癌
预后
neoadjuvant chemotherapy
advanced ovarian cancer
prognosis
